X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by mutations in the ABCD1 gene that encodes the peroxisomal ATP-binding cassette (ABC) transporter subfamily D member 1 protein (ABCD1), which is referred to as the adrenoleukodystrophy protein (ALDP). Induction of the ABCD2 gene, the closest homolog of ABCD1, has been mentioned as a possible therapeutic option for the defective ABCD1 protein in X-ALD. However, little is known about the transcriptional regulation of ABCD2 gene expression. Here, through in silico analysis, we found two putative TCF-4 binding elements between nucleotide positions 2360 and 2260 of the promoter region of the ABCD2 gene. The transcriptional activity of the ABCD2 promoter was strongly increased by ectopic expression of b-catenin and TCF-4. In addition, mutation of either or both TCF-4 binding elements by site-directed mutagenesis decreased promoter activity. This was further validated by the finding that b-catenin and the promoter of the ABCD2 gene were pulled down with a b-catenin antibody in a chromatin immunoprecipitation assay. Moreover, real-time PCR analysis revealed that b-catenin and TCF-4 increased mRNA levels of ABCD2 in both a hepatocellular carcinoma cell line and primary fibroblasts from an X-ALD patient. Interestingly, we found that the levels of very long chain fatty acids were decreased by ectopic expression of ABCD2-GFP as well as b-catenin and TCF-4. Taken together, our results demonstrate for the first time the direct regulation of ABCD2 by b-catenin and TCF-4.
Introduction
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder and is caused by mutations or large deletions of one or more exons in the ABCD1 gene located in Xq28, which encodes the peroxisomal member of the ATP-binding cassette (ABC) transporter subfamily D member 1 (ABCD1), also known as adrenoleukodystrophy protein (ALDP) [1, 2] . X-ALD has an incidence of 1 in 17,000 males, and has several clinical phenotypes, namely severe childhood cerebral form (CCALD, early-onset type), a slowly progressive form called adrenomyeloneuropathy (AMN, late-onset type), and adult cerebral form (ACALD) [3, 4] . Currently, no therapeutic drugs for X-ALD are available, although gene correction of autologous hematopoietic stem cell with a wild-type version of the ABCD1 gene by a lentiviral vector has been shown to provide clinical benefit in X-ALD patients [5] . ABCD1 transports very long chain fatty acids (VLCFAs; those with more than 22 carbon atoms) or their CoA derivatives across the peroxisomal membrane for b-oxidation. Recently, it was demonstrated that human ABCD1 was able to transport VLCFA-CoA into the peroxisome in a yeast system [6] . Dysfunction of ABCD1 results in increased levels of saturated (C24:0 and C26:0) and monounsaturated (C26:1) VLCFAs in the plasma and tissues of X-ALD patients, due to the reduced boxidation of VLCFAs in peroxisomes [7] . Recently, we first reported the generation of X-ALD patient-derived induced pluripotent stem (iPS) cell models [8] . Generated X-ALD iPS cells were successfully differentiated into oligodendrocytes, the main cell type affected by the disease, and notably revealed the underlying pathophysiology which had not been observed in patients' fibroblasts or animal models.
ABCD2 encodes the ALDP-related protein (ALDRP or ABCD2) that share high homology with ABCD1 implying their functional redundancy or functional overlap [9] . Indeed, overexpression of ABCD2 has been shown to normalize peroxisomal b-oxidation and prevent accumulation of VLCFAs in cultured human fibroblast cells obtained from an X-ALD patient [10] [11] [12] and in an Abcd1 knockout mice model [13] . In addition, it has been reported that levels of VLCFAs are restored by pharmacological induction of the ABCD2 gene [10, 14, 15] . Thus, this complementing gene can be an attractive target for X-ALD therapy [16] .
b-catenin is not only a key protein involved in cell-cell adhesion complexes with E-cadherin, but also an important component of the Wnt signaling pathway, which is involved in diverse cellular processes including cell growth, migration, differentiation, gene transcription, development of the nervous system, and self-renewal of stem cells [17] [18] [19] [20] . In the presence of Wnt signaling, cytoplasmic b-catenin translocates into the nucleus [21] where it forms a transcription complex with the lymphoid enhancer factor/ T-cell factor (LEF/TCF) DNA binding protein, resulting in the transcription of target genes [22] . There are four TCF proteins (TCF-1, LEF-1, TCF-3, TCF-4) in mammalian cells [23] . In the absence of Wnt signaling, the TCFs interact with transcriptional repressors (such as Groucho) and gene expression of target genes is inhibited [24] .
Weinhofer et al., via promoter studies, demonstrated that sterol regulatory element-binding proteins (SREBPs), a family of transcription factors that control the metabolism of cholesterol and fatty acids, are involved in transcription of the ABCD2 gene [25, 26] . However, the identities of other transcription factors involved in transcription of the ABCD2 gene are not known. In this study, we investigated putative transcription factors affecting the expression of ABCD2 gene through in silico analysis, and found two putative LEF-1/TCF binding elements between nucleotide positions 2360 and 2260 of the promoter of the ABCD2 gene. To our knowledge, this is the first report that b-catenin and TCF-4 directly regulate the expression of ABCD2; this direct regulation may provide a new drug discovery strategy for X-ALD.
Materials and Methods

Cell Cultures
HepG2 cells (human hepatocellular carcinoma cell line) were cultured in RPMI1640 medium (Sigma) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen). Huh7 cells (human hepatoma cell line) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% antibiotics. Human X-ALD fibroblasts from a single patient with X-ALD (CCALD type; GM04496, Coriell Institute) were cultured in Eagle's minimumessential medium (MEM, Invitrogen) supplemented with 15% FBS and 1% antibiotics. Human dermal fibroblast (HDF) cells were purchased from Invitrogen (#C-004-5C) and were cultured as recommended by the supplier.
Plasmids, Reporter Gene Constructs, and Site-directed Mutagenesis
Expression vectors for Flag-tagged constitutively active bcatenin (b-catenin 4A; S33A, S37A, T41A, S45A), Myc-tagged wild-type TCF-4, and dominant negative TCF-4 (lacking the bcatenin binding site; DN-TCF-4) were obtained from Addgene (plasmid #24204, #16514, #24310, respectively; Cambridge CA) [27, 28] . The human ABCD2-GFP expression vector was purchased from OriGene (#RG211199). Human ABCD2 promoter fragments (21300, 2800, 2500, 21300/2500, 2360, 2260, 2160 bp) were amplified by PCR using i-MAX TM II DNA polymerase (iNtRON biotechnology, Korea) from HDF genomic DNA as a template, and subcloned into the pGL3-basic (Promega) vector. The primer sequences containing restriction sites are listed in Table 1 . The ABCD2 promoter sequence (starting from 21300 bp) was aligned with the sequence of human chromosome 12 (NCBI, Gene ID: 225). Mutations in the LEF-1/TCF binding sites were introduced using the 800-luc reporter plasmid by overlap extension PCR as described previously [29] . In brief, PCRs were performed to generate two DNA fragments (59 fragment and 39 fragment) containing overlapping ends using the following specific primers: mTBE1-59primer, 5-GATG-TAATTCGCCCTGCTCTCTCCTCA -3 and  mTBE1-39 primer, 5-TGAGGAGAGAGCAGGGCGAAT-TACATC -3;  mTBE2-59  primer,  5-TTCAAGGTTAGAAGG-GAAGCTGCGAGG -3 and  mTBE2-39 primer, 5-CCTCGCAGCTTCCCTTC-TAACCTTGAA -3. Putative LEF-1/TCF binding sites are shown in bold, and mutated sequences are underlined. After two rounds of PCR, each full-length construct with the desired mutation (800 bp DNA fragment) was amplified with primers for 800-luc (Table 1) , and subcloned into the pGL3-basic vector. A construct with mutations in both TBEs (Dm TBE) was generated by further mutation of TBE2 from a TBE1-mutated plasmid. The sequences of all reporter constructs were verified by DNA sequencing (SolGent, Korea).
Transfection and Luciferase Reporter Assays
For reporter assays, HepG2 cells were seeded in a 24-well culture plate and transiently transfected with 0.3 mg reporter plasmids and 50 ng of pRL-SV40 plasmid (Promega) containing the Renilla luciferase gene under the control of the Simian virus 40 
. The two putative TCF binding sites (TBE1 and TBE2) are located at nucleotide positions 2324 to 2318 and 2299 to 2293 relative to the ATG translational start site in the upstream sequence of ABCD2 promoter. (B) Each reporter construct was transfected into HepG2 cells using Fugene6 (upper panel), whereas these constructs were electroporated into fibroblast cells from an X-ALD patient with a microporator (lower panel). Thirty-six hours after transfection, cells were harvested, and luciferase activities were determined and normalized by Renilla luciferase activity. Data represent the mean (6SEM) of triplicate experiments and each experiment was repeated three times. *p,0.05; **p,0.01; ns, not significant. doi:10.1371/journal.pone.0056242.g001 promoter using Fugene6 transfection reagent (Roche). The total amount of transfected DNA was kept constant by adding an empty vector. Fibroblasts isolated from an X-ALD patient were electroporated with 0.5 mg reporter plasmids and 0.2 mg of pRL-SV40 plasmid using a microporator transfection system (Neon TM , Invitrogen). Cells were pulsed twice with a voltage of 1,100 (V) for 30 ms. After the two pulses, cells were seeded in a 12-well culture plate. At 36 h after transfection (or electroporation), cells were harvested and luciferase activities were determined by measuring luminescence activity. Data were normalized by Renilla luciferase activity. For overexpression of b-catenin and TCF-4, cells were transfected (or electroporated) with each plasmid using Fugene6 (for HepG2 and Huh7) or a microporator (for X-ALD fibroblasts). Forty-eight hours after transfection, cells were harvested for luciferase activity measurement, western blot analysis, and immunofluorescence staining.
RNAi
Scrambled, b-catenin and ABCD2 siRNA were purchased from Genolution Pharmaceuticals (Korea). HepG2 or X-ALD fibroblasts were transfected with scrambled siRNA (5-ACGUGACAC-GUUCGGAGAA-3), b-catenin siRNA (5-CUGGGACCUUG-CAUAACCU-3) or ABCD2 siRNA (5-GAUUAUGUCUUCAUACAAA-3 and 5-GCAUGAUAAAG-GUUAUACA-3) using Lipofectamine TM RNAiMAX (Invitrogen). Three to four days after transfection, cells were harvested to measure mRNA or protein levels, luciferase activities, and VLCFA levels.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed as described previously [30] . In brief, cells were grown to 80% confluency on 100-mm culture dishes, and then the proteins in cells were cross-linked to DNA by adding formaldehyde for 10 min at RT. Cells were then washed and sonicated to shear chromatin DNA to less than 1000 bp in length. Sheared chromatin was precleared by adding protein G-agarose/ salmon sperm beads (Millipore) and then incubated with either 1 mg anti-rabbit IgG or anti-b-catenin antibodies overnight at 4uC, then for another 2 h at 4uC with protein G-agarose/salmon sperm beads. Following washes, the protein/DNA cross-links were reversed by heating at 65uC overnight, and the DNA fragments eluted. Eluted DNA fragments were used for PCR analysis using the following human ABCD2 promoter-specific primers:
forward, 5-GTTTTGTTCGCCAGCAGATGGCCTGAT-3; reverse, 5-CCGCTGCATCTACCGGGAATGATTCTC-3. Amplified DNA fragments were visualized by agarose gel electrophoresis. 
RNA Isolation and Real-time PCR
Total RNAs were isolated from cells using TRIzol reagent (Invitrogen). The cDNAs were synthesized usingthe iScript TM cDNA synthesis kit (Bio-Rad) from 1 mg of total RNA. Expression of b-catenin, ABCD2, and GAPDH was determined by real-time PCR using SYBRH Premix Ex Taq (Takara) on a CFX Connect TM real-time PCR system (Bio-Rad) according to the manufacturer's instructions. Real-time PCR was performed using the following specific primer sequences: b-catenin-f, 5-ATGTC-CAGCGTTTGGCTGAA-3 and.
b-catenin -r, 5-TGGTCCTCGTCATTTAGCAGTT-3; ABCD1-f, 5-GGAGCTGGTGGCAGAGGA-3 and ABCD1-r, 5-ACAGCCACCATGAGCAGG-3; ABCD2-f, 5-GATAACTGGTCCCAATGGTTG-3 and ABCD2-r, 5-TCCCGAAGACTTCCAAGAGA-3; GAPDH -f, 5-CCCCTCAAGGGCATCCTGGGCTA-3 and GAPDH -r, 5-GAGGTCCACCACCCTGTTGCTGTA-3.
Western Blot Analysis
Total cells lysates were prepared using cell lysis buffer containing protease inhibitor cocktail (Roche) and sodium orthovanadate (Sigma) for 20 min on ice as described previously [31] . The Bradford assay (Bio-Rad) was used to determine protein concentration. Equal amounts of protein were subjected to 10% SDS-PAGE and transferred to a PVDF membrane (Millipore). The membrane was blocked and then incubated for 2 h at RT with one of the following antibodies: anti-b-catenin antibody (Cell Signaling Technology), anti-b-actin and anti-Flag antibody (Sigma), or anti-Myc antibody (Santa Cruz Biotechnology). Following three washes, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research Laboratories) for 1 h at RT. Antibody-labeled proteins were visualized using ECL solution (Amersham Biosciences).
Confocal Microscopy
X-ALD fibroblasts were electroporated with ABCD2-GFP expression plasmid, and cells were seeded on cover glass. Two days after electroporation, cells were washed in phosphatebuffered saline (PBS) and fixed in 4% paraformaldehyde and 0.1% Triton X-100 for 20 min at RT. Cells were further incubated in 5% bovine serum albumin (BSA) for 20 min at RT, and then incubated with anti-PMP70 polyclonal antibody (Millipore) for 2 h at 37uC. After three washes in PBS, cells were incubated with Alexa Fluor 594-conjugated donkey anti-rabbit IgG (Invitrogen) for 1 h at 37uC. After two washes with 0.1% Triton X-100 in PBS and three washes in PBS, cells were analyzed using a confocal microscopy system (Olympus).
VLCFA Analysis
X-ALD fibroblasts were harvested by trypsinization, and the cell pellet (2610 5 cells) was dissolved in PBS. VLCFA analysis was performed by Seoul Clinical Laboratories (Korea) as described previously [32] . VLCFAs were determined by methyl ester formation [33] . In brief, heptacosanoic acid (C27:0) was added as the internal standard to each sample. Then methylene chloride in methanol and acetyl chloride were added and the samples were heated for 1 h at 75uC to allow the formation of methyl esters. After cooling, potassium carbonate solution was added to quench the reaction by neutralization. The resulting fatty acid methyl esters were extracted with hexane solution, followed by extraction with acetonitrile to remove polar compounds. The hexane layer was taken and evaporated to dryness under a gentle stream of nitrogen. The dry residue was reconstituted in hexane for gas chromatography analysis.
Statistical Analysis
The data are presented as means6 SEMs. Student's t-test was used for statistical analysis. p,0.05 was considered statistically significant. 
Results
Identification of LEF-1/TCF Binding Sites within the Promoter of the Human ABCD2 Gene
To investigate transcription factors that could potentially regulate ABCD2, we first analyzed transcription factor binding elements with a proximal region of the promoter of this gene. The upstream sequence (21300 bp) of the ABCD2 promoter subcloned in this study was identical to that of reported sequence on human chromosome 12 (NCBI, Gene ID: 225) (data not shown). By in silico analysis with Genomatix software (MatInspector TM ), we identified the two putative LEF-1/TCF binding elements (TBEs) located at nucleotide positions 2324 to 2318 (TBE1) and 2299 to 2293 (TBE2) within the upstream sequence of the ABCD2 promoter (Fig. 1A) . To investigate the involvement of b-catenin/ TCF-4 on transcriptional activation of the ABCD2 gene, we measured promoter activity from various lengths of the ABCD2 promoter in HepG2 cells expressing constitutively active b-catenin protein [34] . We found that the 21300 bp, 2800 bp, and 2500 bp promoter fragments showed full transcriptional activity compared to the pGL3 basic group (negative control group) (Fig. 1B, upper panel) . However, a fragment containing 21300/ 2500 bp of the ABCD2 promoter showed only a 2.3-fold increase in activity compared to the negative control group (Fig. 1B, upper  panel) . Similar results were obtained for the X-ALD fibroblasts isolated from a patient (Fig. 1B, lower panel) . These data indicate that the region 500 bp upstream of the ABCD2 promoter is an important region for transcriptional activity in both cell types. Interestingly, the 2360 bp fragment, which does not contain a sterol regulatory element (SRE) showed full transcriptional activity in HepG2 cells (Fig. 1B, upper panel) . In addition, the promoter activity of a 2260 bp fragment lacking the two TBEs sequence was less than half that shown by the 2500 bp or 2360 bp fragments (Fig. 1B, upper panel) . In contrast, in the X-ALD fibroblasts, the promoter activity of the 2360 bp fragment was half of that obtained from the 2500 bp fragment, while the promoter activity of the 2260 bp fragment was significantly lower than that of the 2360 bp fragment (Fig. 1B, lower panel) . These 
Activation of ABCD2 Promoter by b-catenin and TCF-4
To further investigate transcriptional regulation of ABCD2, cells were transfected with the 800-Luc reporter plasmid alone or combinations with b-catenin active mutant (4A), wild-type TCF-4, dominant negative (DN)-TCF-4 expression plasmids. As shown in Fig. 2A , expression of the active b-catenin mutant protein resulted in only 2.6-fold activation of the ABCD2 promoter (Fig. 2A, lane 2) due to the presence of an endogenous active mutant form of bcatenin in HepG2 cells [34] . Interestingly, the promoter activity of the ABCD2 gene was 15-fold greater in cells expressing wild type TCF-4 protein than cells expressing empty vector (Fig. 2A, lane 3) . In contrast, promoter activity was slightly decreased in cells that expressed DN-TCF-4 protein (Fig. 2A, lane 5) . These results strongly suggest that b-catenin and TCF-4 interact to activate transcription of the ABCD2 gene. Consistent with these results, we found that cotransfection of b-catenin and wild-type TCF-4 expression plasmids resulted in a 21.1-fold induction in promoter activity (Fig. 2A, lane 4) , whereas cotransfection of b-catenin and DN-TCF-4 plasmids resulted in only a 2.5-fold induction in promoter activity (Fig. 2A, lane 6) .
To determine the role of b-catenin in ABCD2 promoter transactivation in HepG2 cells, endogenous b-catenin expression Figure 5 . Levels of VLCFAs in fibroblasts from an X-ALD patient were restored by ectopic expression of ABCD2-GFP. Primary fibroblasts isolated from an X-ALD patient were electroporated with either GFP or ABCD2-GFP expressing plasmid using a microporator. (A) At 48 h after electroporation, cells were fixed and incubated with anti-PMP70 antibody for 2 h. After washing with PBS, cells were incubated with Alexa Fluor 594-conjugated donkey anti-rabbit IgG for 1 h. Immunofluorescence staining was analyzed using a confocal microscopy system. Cells were counterstained with 49,6-diamidino-2-phenylindole (DAPI) to label nuclei. was knocked-down using specific siRNAs. Real-time PCR analysis revealed that the expressions of both wild-type (WT) and active mutant forms (Mut) of b-catenin in HepG2 cells were efficiently reduced by siRNA transfection (Fig. 2B, right   panel) . Subsequently, we showed that the promoter activity of the ABCD2 gene was decreased by b-catenin silencing (Fig. 2B,  left panel) . These data indicate that both b-catenin and TCF-4 are required for the transcriptional activation of ABCD2. 
Contribution of the Two TBE Sites within the ABCD2 Promoter to b-catenin/TCF-4 Mediated Transcriptional Activation
To determine whether the two putative TBEs identified in this study are required for b-catenin/TCF-4-mediated transcriptional activation, we introduced mutations into the TBEs and performed luciferase assays. To destroy the binding sequence of LEF-1/TCF, we mutated two nucleotides within each TBE motif (Fig. 3A, lower  panel) . First, we investigated the effect of mutations in TBE sites on promoter activation in Huh7 cells. Mutation of either of the TBE sites significantly decreased transcriptional activation by bcatenin/TCF-4 (Fig. S1) . However, the greatest reduction was observed when both TBE sites were mutated (Fig. S1 ), hence we used the construct with mutations of both TBE sites for further experiments in HepG2 cells. As expected, we found that mutation of both TBE sites strongly reduced transcriptional activation by bcatenin/TCF-4 as well as basal levels of transcription (Fig. 3A) . In the absence of ectopic expression of b-catenin/TCF-4, luciferase activity was decreased 5-fold by of the TBE mutations. Moreover, ectopic expression of b-catenin/TCF resulted in a 10.8-fold induction in ABCD2 promoter activity when wild-type TBEs sequences were present, compared to a 4.5-fold induction when the TBEs were both mutated (Fig. 3A) . These results indicate that b-catenin/TCF-4-mediated transcriptional activation of ABCD2 can be blocked by mutating the TCF-4 binding elements in the ABCD2 promoter region. Similar results were obtained in the X-ALD fibroblasts (Fig. S2) .
To determine if the ABCD2 promoter is a direct target of the bcatenin/TCF-4 complex, we performed a chromatin immunoprecipitation (ChIP) assay. We used either normal rabbit IgG or bcatenin antibodies for ChIP, and amplified the DNA using specific primers for the ABCD2 promoter containing the two TBEs. As shown in Fig. 3B , the ABCD2 promoter was immunoprecipitated by the b-catenin antibody, but was not immunoprecipitated by the normal IgG antibody. These data indicate that a transcription factor complex containing b-catenin binds directly to the ABCD2 promoter.
Upregulation of ABCD2 Gene Expression via b-catenin and TCF-4
We examined whether mRNA level of ABCD2 gene was increased by ectopic expression of active mutant b-catenin (4A) and wild-type TCF-4 in HepG2 cells. mRNA expression of ABCD2 was compared between control vector-transfected or bcatenin and TCF-4-transfected cells after total RNA extraction. As shown in Fig. 4A , ABCD2 expression was elevated by ectopic expression of b-catenin and TCF-4. In contrast, ABCD1 expression was unaffected by these proteins (Fig. 4A) . We also confirmed the increased expression of transfected b-catenin and TCF-4 proteins by western blot analysis (Fig. 4A, lower panel) . Unfortunately, we were unable to detect an increased protein level of ABCD2 as a result of commercially available antibodies not working against the ABCD2 protein. Conversely, transcript expression of ABCD2 was significantly decreased by siRNA-mediated b-catenin knockdown in HepG2 cells (Fig. 4B) . However, ABCD1 expression was not decreased by b-catenin knockdown (Fig. 4B) . We verified the knockdown of b-catenin by western blotting (Fig. 4B, lower panel) using a specific antibody against b-catenin.
Restoration of VLCFA Levels in the Fibroblasts Derived from an X-ALD Patient by Ectopic Expression of ABCD2-GFP
Functional replacement of the ABCD1 protein (ALDP) by the ABCD2 protein (ALDRP) has been shown to reduce VLCFA accumulation in fibroblast cells isolated from X-ALD patients [10, 12] . To confirm this finding in our cell system, either GFP or ABCD2-GFP expression vectors were electroporated into fibroblast cells isolated from an X-ALD patient. A punctuate spot pattern of GFP signals from the ABCD2-GFP protein was detected outside of the nucleus, and this pattern merged perfectly with fluorescent signals from PMP70, which is a peroxisomal marker protein (Fig. 5A) . These results indicate that the ABCD2-GFP fusion protein is able to correctly target the peroxisomal membrane.
Since C26:0/C22:0 ratio is being used widely for diagnosing X-ALD [33] , we analyzed the ratio of C26:0/C22:0 to determine if the ABCD2 protein had a compensatory effect. We found that ectopic expression of ABCD2-GFP by electroporation resulted in a 10-fold induction in ABCD2-expression in fibroblasts relative to the negative control (Fig. 5B) . Interestingly, we observed that ectopic expression of GFP-tagged ABCD2 resulted in a decrease in the ratio of C26:0/C22:0, indicating that accumulated VLCFA levels were reduced in the fibroblast cells from an X-ALD patient by ectopic ABCD2 (Fig. 5C ). These results in our cell system are consistent with previous studies that reported that ABCD2 is functionally redundant with ABCD1 [10] [11] [12] .
b-catenin and TCF-4 Regulate the Levels of VLCFAs via Induction of ABCD2 Gene
We next asked whether VLCFA levels decreased in response to b-catenin and TCF-4-induced ABCD2 induction in X-ALD fibroblasts. X-ALD fibroblasts were electroporated with either GFP or active b-catenin and TCF-4 expression vectors. We showed that mRNA level of the ABCD2 gene was increased by overexpression of b-catenin and TCF-4 using real-time PCR analysis (Fig. 6A, upper panel) . Interestingly, we found that the ratio of C26:0/C22:0 was significantly decreased by overexpression of these proteins (Fig. 6B) . Conversely, mRNA levels of ABCD2 decreased when b-catenin was silenced (Fig. 7A) . In addition, silencing of b-catenin resulted in a significant increase in VLCFA levels (Fig. 7B) . We further investigated whether bcatenin/TCF-4-dependent change of C26:0/C22:0 is mediated by induction of ABCD2. For this purpose, X-ALD fibroblasts were transfected with ABCD2 siRNA. We observed that b-catenin/ TCF-4-dependent change of C26:0/C22:0 was abolished by ABCD2 knockdown in X-ALD fibroblasts (Fig. 8) . These data indicate that b-catenin/TCF-4 are able to regulate the levels of VLCFAs through ABCD2 gene induction.
Discussion
X-ALD, caused by mutations of the ABCD1 gene, is associated with the accumulation of VLCFAs in the plasma and tissues of patients [35] . At present, no therapeutic drug for X-ALD is available; although Lorenzo's oil reduces the levels of plasma VLCFA with little or no effect on the disease progression [36] . The cholesterol-lowing drug, lovastatin, was suggested as a potential therapeutic drug for X-ALD [37, 38] , but did not decrease VLCFA levels in a placebo-controlled clinical trial [39] .
Induction of ABCD2 may be a promising treatment option for X-ALD because expression of this protein can decrease VCLFA levels in fibroblasts. However, little is known about transcriptional activation of this gene or the mechanism of action of drugs that have been reported to activate this gene, although a binding site for SREBP1 (SRE at position 2401/2391) in the ABCD2 promoter has been reported [25] . We therefore investigated transcription factors involved in the regulation of ABCD2 gene expression.
By in silico analysis using Genomatix software (MatInspector TM ), we found two putative LEF-1/TCF binding elements (TBEs) (Fig. 1A) in the promoter region of ABCD2 in addition to the GC and CCAAT boxes reported in earlier studies [40, 41] . The TBE1 sequence (CTTTGCT) is one nucleotide different from the TCF-4 binding sequence (CTTTG(A/T)(A/ T)) [42] , whereas the TBE2 sequence (TTCAAAG) is an inverted perfect match of the consensus sequence (Fig. 1A) . To investigate if these sites are involved in ABCD2 gene transcription, we performed luciferase reporter assays using various lengths of the ABCD2 promoter. Because the promoter of the ABCD2 gene has putative TBEs, we chose HepG2 cells that contain active b-catenin protein to investigate transcriptional activation. In both HepG2 cells and fibroblasts from an X-ALD patient, the 2260 promoter fragment showed minimal activity, while the activity of the 2360 fragment differed according to cellular context (Fig. 1) . We further demonstrated that TBEs are involved in transcriptional regulation of ABCD2 by performing a mutagenesis study (Fig. 3A) . Interestingly, we found that the 2260 fragment still had promoter activity in both cell types even when the TBE sequences were deleted (Fig. 1A and 1B) , indicating the existence of another response element within the promoter region.
Next, we showed that the promoter activity of ABCD2 was elevated by ectopic expression of b-catenin and TCF-4 ( Fig. 2A,  lane 4) . We confirmed this finding in Huh7 cells that do not express active b-catenin [43] (Fig. S3 ) and in CCALD fibroblast cells (data not shown). Site-directed mutagenesis results provided direct evidence that the TBEs within the ABCD2 promoter are functionally involved in ABCD2 transcriptional regulation (Fig. 3A) . Through ChIP assays, we showed that b-catenin containing complexes bind directly to the promoter region of the ABCD2 gene (Fig. 3B) . In addition, we demonstrated that gene expression of ABCD2 is upregulated by overexpression of bcatenin/TCF-4 (Figs. 4A and 6A) while downregulation occurs by silencing of b-catenin (Figs. 4B and 7A) in both HepG2 cells and X-ALD fibroblasts. Moreover, we showed that b-catenin/TCF-4 reduced the ratio of C26:0/C22:0 (Fig. 6B) as well as the levels of C24:0 and C26:0 (data not shown) in the fibroblasts from an X-ALD patient. Finally, we showed that this effect was reversed by bcatenin silencing (Fig. 7B) .
Transcription factors such as SREBPs [25, 26] , triiodothyronine (T 3 )-liganded thyroid hormone receptor a (TRa)/SREBP-1 [44] , peroxisome proliferator-activated receptor a (PPARa) [42] , and the retinoic X receptor (RXR)/cis-retinoic acid [45] have been reported to be regulators of the ABCD2 gene. However, we found that b-catenin and TCF-4 not only increased transcription of the ABCD2 gene, but also decreased levels of VLCFAs according to the level of ABCD2 induction. We therefore speculate that induction of ABCD2 by b-catenin and TCF-4 may decrease levels of VLCFAs.
In this study, we demonstrated direct regulation of ABCD2 gene expression by b-catenin and TCF-4, which are members of the canonical Wnt signaling pathway. These findings may provide a new strategy for developing drugs to treat X-ALD. Figure S1 Mutation of TBE sites within the ABCD2 promoter decreased b-catenin/TCF-4 mediated promoter activity in Huh7 cells. Huh7 cells were cotransfected with the indicated expression plasmids along with either wild-type (WT) 800-Luc reporter plasmid containing wild-type (WT) TBE sequences or 800-Luc reporter plasmids containing the mutation of one or both TBE sites of the ABCD2 promoter (mTBE1, mTBE2, and DmTBE, respectively). 
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